4.0551.12% ( +0.045 )
Trading: Oct 13, 12:50:49 (EDT)Current ValuationThe current P/E ratio is -1.01, within the reasonable range, cheaper than 48.98% of the time in the past 3 years, and the industry ranks 82/173, the industry Median -0.92.
-1.01xP/E
$4.01Stock price
$-3.95Earnings per share
-1.01xP/E
Stock price$4.01Earnings per share$-3.95
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.03x
- Typical range
- -1.61x–-0.44x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -12.05x | 141.71% | $12.81B |
GKOSUSGlaukos | -52.70x | 75.37% | $9.91B |
TFXUSTeleflex | -5.16x | 118.39% | $5.33B |
PLSEUSPulse Biosciences | -46.73x | 27.55% | $3.74B |
IRTCUSIRhythm | -252.13x | 70.88% | $3.52B |
BFLYUSButterfly Network | -30.42x | 31.45% | $2.28B |
AXGNUSAxogen | -64.90x | 16.18% | $2.18B |
ASSTUSStrive | -1.96x | 63.23% | $1.92B |
ATECUSAlphatec | -15.80x | 41.67% | $1.74B |
NVCRUSNovocure | -11.54x | 1.23% | $1.71B |
KMTSUSKestra Medical Tech | -10.52x | 0.94% | $1.58B |
DRTSUSAlpha Tau Medical | -14.22x | -- | $1.32B |
TNDMUSTandem Diabetes | -18.08x | 77.60% | $1.14B |
PRCTUSPROCEPT BioRobotics | -10.21x | 3.47% | $1.12B |
IARTUSIntegra LifeSciences | -150.24x | 109.42% | $1.09B |
AORTUSArtivion | -332.94x | 266.67% | $1.06B |
ENOVUSEnovis | -0.96x | 100.97% | $1.05B |
CBLLUSCeribell | -14.69x | 35.15% | $969.43M |
BBNXUSBeta Bionics | -12.88x | 11.45% | $940.18M |
QDELUSQuidelOrtho | -0.87x | 75.33% | $908.62M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
